Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE BESYLATE BENAZEPRIL HYDROCHLORIDE versus CAPOZIDE 50 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE BESYLATE BENAZEPRIL HYDROCHLORIDE versus CAPOZIDE 50 15.
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE vs CAPOZIDE 50/15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation, decreased aldosterone secretion, and reduced blood pressure.
CAPOZIDE 50/15 combines captopril (angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- cotransporter in distal convoluted tubules.
Oral, 1 capsule (amlodipine 2.5-10 mg / benazepril 10-40 mg) once daily. Start with amlodipine 2.5 mg / benazepril 10 mg, titrate based on response.
Oral, 1 tablet (captopril 50 mg / hydrochlorothiazide 15 mg) once daily. May increase to 2 tablets daily in divided doses if needed.
None Documented
None Documented
Amlodipine: terminal elimination half-life 30-50 hours (mean ~35 h), allowing once-daily dosing. Benazeprilat: effective half-life 10-11 hours; terminal half-life ~22 hours, with prolonged effects in renal impairment.
Captopril: terminal half-life ~2 hours (in patients with normal renal function; prolonged in renal impairment to 21-36 hours). Hydrochlorothiazide: half-life 6-15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: dosing interval affected by renal function.
Amlodipine: ~90% metabolized to inactive metabolites, ~10% excreted unchanged in urine; metabolites excreted renally (~60%) and fecally (~20-25%). Benazepril: hydrolyzed to benazeprilat, which undergoes renal excretion (~33% as unchanged drug and metabolites) and biliary/fecal excretion (~33%), with the remainder via other routes.
Captopril: renal excretion of unchanged drug and metabolites, primarily in urine (60-75%), with ~20% as unchanged captopril; small amount in feces (5-10%). Hydrochlorothiazide: renal excretion (95% unchanged), <5% via biliary/fecal.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor and Diuretic Combination